April 17, 2014

Study: HPV Rate Lower Among Unvaccinated versus Vaccinated

Has the CDC done a study on vaccinated vs unvaccinated children Study: HPV Rate Lower Among Unvaccinated versus Vaccinated

 

Health Impact News Editor Comments:

Once again, we have an example of a study funded by pro-vaccine researchers that looks at a sub-set of the population and compares those who are vaccinated versus those who are not vaccinated, and finds a result they were not expecting. So they spin the study to make it seem like the result was the one they were trying to prove, and then the mainstream media publishes the spin, instead of what the actual study showed. We saw that earlier this year with a JAMA study looking at vaccinated versus under-vaccinated children.

The latest occurrence of this phenomenon is a CDC study looking at Human Papillomavirus occurrence and vaccine rates. This study was headline news in all the major media outlets last week with headlines such as: “HPV vaccine cut infection by half in teen girls” and “news” stories that looked like they were promo pieces written by the vaccine manufacturer.

Sharlene Bidini has looked at the actual study, however, and points out a few facts that the mainstream media left out (probably because they never bothered to read the study itself.)

Assessing the Overall Impact of the HPV Vaccine

by Sharlene Bidini, RD, CSO
The Oncology Nurse Community

Excerpts:

A new study, published in the Journal of Infectious Diseases, provides new data regarding the effectiveness of the Human Papillomavirus (HPV) vaccine in reducing HPV prevalence.

The Advisory Committee on Immunization Practices (ACIP) started recommending routine Human Papillomavirus (HPV) vaccination in June 2006. In order to estimate the effectiveness of the HPV vaccine, researchers used data from the National Health and Nutrition Examination Surveys (NHANES), 2003-2006 and 2007-2010.

Here is the conclusion from the study: Within four years of vaccine introduction, the vaccine-type HPV prevalence decreased among females aged 14-19 years despite low vaccine uptake. The estimated vaccine effectiveness was high.

The study conclusion (drawn from the NHANES survey 2007-2010) was based on 740 girls, aged 14-19. However, only 358 were sexually active, and of those, only 111 had at least 1 HPV shot. If the study authors were trying to determine vaccine effectiveness, why did they include the girls who had not received a single HPV shot or did not report having sex?

An interesting fact that was not shared, was that among those 740 girls, the HPV prevalence of high-risk, non-vaccine types declined 20.7 percent (from 20.7 percent to 16.4 percent).

Some healthcare professionals may be quick to assume that the HPV reduction was an obvious outcome after mass immunization. However, the data provided in Table 3 clearly demonstrates that the unvaccinated girls in this group had the best outcome. The study table separates the HPV prevalence into three categories: overall, vaccinated, and unvaccinated.

The overall prevalence of HPV in the study period 2007-2010 was 42.9 percent when the vaccinated and unvaccinated girls are combined. In 2007-2010, the overall prevalence of HPV was 50 percent in the vaccinated girls (14-19 years), but only 38.6 percent in the unvaccinated girls of the same age. Therefore, HPV prevalence dropped 27.3 percent in the unvaccinated girls, but only declined by 5.8 percent in the vaccinated group.

Read the Full Article Here: http://www.theonc.org/author.asp?section_id=2414&doc_id=265168

Vaccine Epidemic
by Louise Kuo Habakus and Mary Holland J.D.

Vaccine Epidemic bookcover Study: HPV Rate Lower Among Unvaccinated versus Vaccinated

 FREE Shipping Available!

More Info

0 commentsback to post

Other articlesgo to homepage

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

U.S Congressman: CDC Can’t be Trusted Regarding Vaccine Safety

Congressman Bill Posey’s strong resolve and demands for transparency were evident as he discussed the Center for Disease Control (CDC)’s handling of vaccine safety studies which affect “our most precious resource in our nation – our children.” The 30-minute interview, conducted by vaccine industry watchdog, PhD biochemist Brian Hooker, delves into what Posey called “the incestuous relationship between the public health community and the vaccine makers and public officials.”

The Florida legislator, known as “Mr. Accountabililty,” did not mince words when criticizing current and past CDC officials including indicted fraudster Dr. Poul Thorsen; CDC director turned Merck Vaccine President Dr. Julie Gerberding; and the agency’s current spokesperson regarding autism and vaccines, Dr. Coleen Boyle.

Congressman Posey said, “The CDC can’t be trusted regarding investigating vaccine safety. Huge conflict of interest. I think the CDC should be investigated.”

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

In an interview with Dr. Bernard Dalbergue, a former pharmaceutical industry physician with Gardasil manufacturer Merck, he predicts that Gardasil will become the greatest medical scandal of all time. Dr. Dalbergue believes that at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill young girls, serves no other purpose than to generate profit for the manufacturers.

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

An important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia. In an interview conducted by our colleagues at ANH-Europe, Dr. Peter C. Gøtzsche exposes the flaws of the drug approval system, our reliance on dangerous drugs, and the deadly co-dependence between regulators and industry. Dr. Gøtzsche is co-founder of the highly respected Cochrane Collaboration and Cochrane Reviews, a leading journal of evidence-based medicine. The interview is particularly timely now that the FDA has decided to remove restrictions on the dangerous drug Avandia.

Dr. Gøtzsche’s new book, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, points out that the pharmaceutical industry is allowed to test their own drugs, and thus effectively be their own judge. He calls this a threat to safe medicine and asks for open access to all research data, including raw data, because otherwise, data can be easily suppressed and conclusions manipulated by industry.

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical marijuana, or cannabis, is legal in 20 US states, where it is used for a variety of medical conditions such as mood disorders, pain disorders, multiple sclerosis, and even cancer. Parents of children with epilepsy met at a news conference to share their dismay that Governor Mark Dayton refuses to legalize medical marijuana. About 85 percent to 95 percent of Americans are in favor of medical cannabis, and nearly 60 percent are in favor of legalizing marijuana. Cannabis shows outstanding promise as a medicinal plant, largely due to its cannabidiol (CBD) content. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body.

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published recently in the Journal of the American Medical Association.

A team of researchers at the University of Pittsburgh Medical Center examined the boards of the 50 largest drug companies by global sales (excluding three companies that were not publicly traded). The researchers found that 40 percent — 19 companies — had at least one board member who also held a leadership role at an academic medical center. Sixteen of the 17 companies based in the United States had at least one. Several had more than one. All told, the research team found that 41 of the companies’ 2012 board members held leadership positions at academic medical centers. Six of the 41 were pharmaceutical company executives who served on hospital boards of directors or held other leadership posts.

The authors wrote that when academic medical leaders serve on pharmaceutical company boards, it can lead to conflicts not only for individuals, but for the critically important health care institutions they guide.

read more


Get the news right in your inbox!